# Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study

> **NCT07311915** · NA · NOT_YET_RECRUITING · sponsor: **Zhongda Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Propranolol combined with novel endocrine therapy and androgen deprivation therapy

## Key facts

- **NCT ID:** NCT07311915
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311915, "Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07311915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*